Navigation Links
Debiopharm Group™ and Aurigene Nominate Development Candidate
Date:9/13/2010

LAUSANNE, Switzerland, and BANGALORE, India, Sept. 13 /PRNewswire/ -- Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and Aurigene Discovery Technologies Ltd. (Aurigene), a Bangalore-based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre-IND drug candidates, today announced the successful nomination of a development candidate, Debio 0617, a novel inhibitor of an undisclosed oncology pathway. Debio 0617 has started IND enabling studies and is expected to enter clinical development in 2012.

Debiopharm and Aurigene have been collaborating for five years. In November 2008, Aurigene's fragment-based drug delivery technology platform had generated potent leads against the target. Both companies signed an exclusive worldwide license agreement, excluding the territories of Japan and the rest of Asia, to develop and commercialise Debio 0617. They defined a target molecular profile at the beginning of the program. Now, 20 months later, both teams have successfully identified the development candidate which better fits the initial target molecular profile.

"What exciting news! As we expected, this program has delivered a development candidate molecule as well as several potential follow-on compounds," said Rolland-Yves Mauvernay, president and founder of Debiopharm Group™. "Once again, Aurigene has demonstrated its dedication and professionalism."

"This represents an important success not just for this scientific program, but also for the strategic path that was established through this agreement between Debiopharm and Aurigene. This is a truly synergistic relationship that takes advantage of the proven experience, expertise and processes at Debiopharm, coupled with the speed, flexibility and high-qualit
'/>"/>

SOURCE Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025
2. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
3. Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
4. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
5. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
6. Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
7. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
8. Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients
9. Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
10. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award
11. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015  CryoLife, Inc. (NYSE: CRY ), ... on cardiac and vascular surgery, announced today that it ... Food and Drug Administration ("FDA") verifying that the Company ... the warning letter it received from the FDA in ... re-inspection in March 2015 by the FDA at CryoLife,s ...
(Date:4/27/2015)...   AMC Health , a leading provider of ... care that are transforming chronic care and population health ... May 2-5 at the Los Angeles ... information about how their innovative programs, solutions and services ... healthcare delivery at Booth #2116 and during their joint ...
(Date:4/27/2015)... April 27, 2015 Harwood Feffer LLP ( ... of directors of Aerie Pharmaceuticals, Inc. ("Aerie" or the ... has breached its fiduciary duties to shareholders. ... release announcing results from its first Phase 3 registration ... disclosed that in the trial, Rhopressa failed to meet ...
Breaking Medicine Technology:CryoLife Announces Resolution of FDA Warning Letter 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 2AMC Health to Showcase Advances in Monitored Care at ATA 2015 3AMC Health to Showcase Advances in Monitored Care at ATA 2015 4Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2
... NORTH WALES, Pa., Feb. 16, 2011 AirPal, a ... received notification of allowance from the U.S. Patent Office ... position patients for situations such as difficult airway management, ... The company, founded in 1982, now holds more than ...
... and Willkie Farr & Gallagher will host an anti-bribery ... trends on French companies operating internationally. The seminar will ... of Willkie Farr & Gallagher. Please visit www.traceinternational.org ... event or contact king@traceinternational.org French ...
Cached Medicine Technology:AirPal Receives Patent for Inflatable Patient Positioning Systems 2TRACE and Willkie Farr Announce Anti-Bribery Seminar in Paris 2
(Date:4/27/2015)... 27, 2015 "Understanding Mental Disorders: Your ... 1 by American Psychiatric Publishing, a division of the ... 1pm at the National Press Club in Washington, D.C.. ... moderated by APA President Paul Summergrad, MD. Guest speakers ... the foreword to the book; Paul Gionfriddo, President and ...
(Date:4/27/2015)... Md. (PRWEB) April 27, 2015 On May ... ones will ask their social media friends around the world ... dismissed as asthma. , May 5 is World Pulmonary ... (PHA), a leader in the global PH community, will take ... or high blood pressure of the lungs. PH is an ...
(Date:4/27/2015)... According to a recent report from NIDCR ... back pain, TMJ disorders are the second most ... In addition, the report revealed that TMJ disorders affect ... an estimated 4 billion dollars annually. , These estimates ... unrelated symptoms such as headaches, neck pain, tenderness of ...
(Date:4/27/2015)... As ISO 27001 has quickly become the ... all sizes and in all industries, Pivot Point Security ... ISO 27001 certification. The information security audit firm has ... ISO 27001 certification. Pivot Point's commitment to ISO 27001 ... of Lead Implementers and Auditors the company employs (now ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Guided by ... field of patient experience and its collaboration with organizations ... The Beryl Institute identifies eight essential actions ... The Beryl Institute believes organizations and systems committed to ... Identify and support accountable leadership with committed time ...
Breaking Medicine News(10 mins):Health News:American Psychiatric Association, Patrick Kennedy To Debut New Consumer Guidebook “Understanding Mental Disorders” 2Health News:Pulmonary Hypertension Association Marks World PH Day on May 5 with a Worldwide Lifesaving Social Media Blitz 2Health News:Pulmonary Hypertension Association Marks World PH Day on May 5 with a Worldwide Lifesaving Social Media Blitz 3Health News:Dentist in Graham NC Reveals that a Jaw Disorder May Be the Cause of Chronic Headaches and Back Pain 2Health News:Six Additional New ISO 27001 Lead Implementers Certified for Pivot Point Security 2Health News:Guiding Principles for Patient Experience Excellence Identified by The Beryl Institute 2
... breakdown of retinoic acid, derived from vitamin A, is ... models of human prostate cancer, say investigators from the ... of the agent VN/14-1 resulted in up to a ... with human prostate cancer cells, reported Aakanksha Khandelwal, Ph.D., ...
... Study Supported Efficacy, Safety and Tolerability of ... 13-17 with Schizophrenia -, TOKYO and PRINCETON, ... Bristol-Myers Squibb Company (NYSE: BMY ) announced ... approved the supplemental New,Drug Application for the atypical ...
... increase 21% over the ... FARMINGTON, Conn., Nov. 6 Darwin Professional,Underwriters, Inc. ("Darwin," the ... for the third quarter ended September 30,2007. Highlights include: -- ... Third quarter gross premiums written are 5.9% ...
... ARLINGTON, Va., Nov. 6 In ... Network,s, (http://www.HealthCentral.com ) MyDiabetesCentral.com has launched ... of those with diabetes and provides,important ... this condition. The,special section, which can ...
... 6 QED International Associates Inc.,administrator for the ... portfolios, today announced that effective at the,opening of ... Ltd.,(Nasdaq: GIVN ) will replace Dade Behring ... Diagnostics Index, and Inverness Medical Innovations,(Amex: IMA ...
... Toronto, ON (November 6, 2007) Canadian researchers expect to ... network of hundreds of thousands of people who volunteer their ... complex problems. , The research team, led by Dr. ... at Princess Margaret Hospital and University Health Network, are the ...
Cached Medicine News:Health News:Drug slows prostate tumor growth by keeping vitamin A active 2Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 2Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 3Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 4Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 5Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 6Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 7Health News:U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia 8Health News:Darwin Professional Underwriters, Inc. Reports Record Net Income of $8.4 Million for the Third Quarter 2Health News:Darwin Professional Underwriters, Inc. Reports Record Net Income of $8.4 Million for the Third Quarter 3Health News:Darwin Professional Underwriters, Inc. Reports Record Net Income of $8.4 Million for the Third Quarter 4Health News:Darwin Professional Underwriters, Inc. Reports Record Net Income of $8.4 Million for the Third Quarter 5Health News:Darwin Professional Underwriters, Inc. Reports Record Net Income of $8.4 Million for the Third Quarter 6Health News:Darwin Professional Underwriters, Inc. Reports Record Net Income of $8.4 Million for the Third Quarter 7Health News:The HealthCentral Network's MyDiabetesCentral.com Promotes Awareness of Diabetes 2Health News:The HealthCentral Network's MyDiabetesCentral.com Promotes Awareness of Diabetes 3Health News:QED International Associates Announces Changes to the HealthShares(TM) Composite, and the HealthShares(TM) Diagnostics Indexes 2Health News:IBM world community grid squeezes decades of cancer research into 2 years 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: